Trump pressures Pfizer and other pharmaceutical companies to agree to a 40% price reduction for selling drugs to patients

AASTOCKS
2025.07.17 16:26

Bristol Myers Squibb (BMY.US) and Pfizer (PFE.US) announced on Thursday that they will begin selling their blockbuster blood thinner Eliquis directly to patients at a discount of over 40% to comply with the Trump administration's new policy aimed at lowering drug prices.

The two companies will bypass traditional intermediaries, including pharmacy benefit managers and insurance companies, reducing the monthly cost of the drug from the list price of about $606 to $346. Starting September 8, uninsured, underinsured, and cash-paying patients will be able to purchase the medication directly through the Eliquis 360 support program, which will deliver prescriptions directly to patients' homes

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.